Interleukin‐11/gp130 upregulates MMP‐13 expression and cell migration in OSCC by activating PI3K/Akt and AP‐1 signaling
Authors:
- 19 October 2022
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 237 (12) , 4551-4562
Abstract
Oral squamous cell carcinoma (OSCC) is an extremely common head and neck cancer with a poor 5‐year survival rate, especially in cases of metastatic disease. Interleukin (IL)‐11 reportedly promotes cell growth and the epithelial–mesenchymal transition process in metastasis. However, the molecular mechanisms of IL‐11 in OSCC metastasis are unclear. This study found that IL‐11 upregulates matrix metalloproteinase 13 (MMP‐13) expression in OSCC via the IL‐11 receptor alpha subunit/glycoprotein 130 receptors that activate phosphatidyl‐inositol 3‐kinase, Ak strain transforming, and activator protein 1 signaling, which subsequently enhance MMP‐13‐induced tumor metastasis. TIMER2.0 analysis revealed a positive correlation between MMP‐13 and IL‐11 levels (r = 0.454). Moreover, a strong positive association was observed between higher levels of IL‐11 expression in OSCC tissue (p < 0.01), lymph node metastasis (p = 0.0154), and clinical disease stage (p = 0.0337). IL‐11 knockdown suppressed the migration of OSCC cells (p < 0.05). The evidence indicates that IL‐11 can serve as a new molecular therapeutic target in OSCC metastasis.Keywords
This publication has 38 references indexed in Scilit:
- Cancer-associated fibroblasts-stimulated interleukin-11 promotes metastasis of gastric cancer cells mediated by upregulation of MUC1Experimental Cell Research, 2018
- Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future SuccessesMolecular Cancer Therapeutics, 2018
- Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCCOral Oncology, 2018
- Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapyPLOS ONE, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer TherapyMolecular Cancer Therapeutics, 2016
- Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand EfficienciesInternational Journal of Molecular Sciences, 2016
- Marimastat: the clinical development of a matrix metalloproteinase inhibitorExpert Opinion on Investigational Drugs, 2000
- Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseasesExpert Opinion on Investigational Drugs, 2000
- Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and MarimastatPharmacology & Therapeutics, 1997